Glucagon and alpha-cells as a novel therapeutic target in the management of diabetes mellitus
https://doi.org/10.14341/2072-0351-815
Abstract
For the past several years, a number of studies addressed glucagon and its role in glycemic homeostasis and the development of diabetes mellitus. Current review discusses basic developmental stages of pancreatic islets with special regard for the role of beta-cells and basic mechanisms of glucagon function. We also highlight promising approaches to diabetes compensation based on adjustment of glucagon secretion.
About the Authors
Nina Alexandrovna Petunina
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
Lyubov' Valentinovna Trukhina
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
Elena Igorevna Sinicyna
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
Marina Vladimirovna Shestakova
I.M. Sechenov First Moscow State Medical University, Moscow; Endocrinology Research Centre, Moscow
Russian Federation
Russian Federation
References
1. Lefebvre PJ. Early milestones in glucagon research. Diabetes Obes Metab. 2011;13 Suppl 1:1-4. DOI: http://dx.doi.org/10.1111/j.1463-1326.2011.01437.x
2. Bramswig NC, Kaestner KH. Transcriptional regulation of alpha-cell differentiation. Diabetes Obes Metab. 2011;13 Suppl 1:13-20. DOI: http://dx.doi.org/10.1111/j.1463-1326.2011.01440.x
3. Cnop M, Hughes SJ, Igoillo-Esteve M, Hoppa MB, Sayyed F, van de Laar L, et al. The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia. 2010;53(2):321-330. DOI: http://dx.doi.org/10.1007/s00125-009-1562-x [PubMed]
4. Li HJ, Ray SK, Singh NK, Johnston B, Leiter AB. Basic helix-loop-helix transcription factors and enteroendocrine cell differentiation. Diabetes Obes Metab. 2011;13 Suppl 1:5-12. DOI: http://dx.doi.org/10.1111/j.1463-1326.2011.01438.x
5. Collombat P, Hecksher-Sorensen J, Krull J, Berger J, Riedel D, Herrera PL, et al. Embryonic endocrine pancreas and mature beta cells acquire alpha and PP cell phenotypes upon Arx misexpression. Journal of Clinical Investigation. 2007;117(4):961-970. DOI: http://dx.doi.org/10.1172/JCI29115
6. Collombat P, Mansouri A, Hecksher-Sorensen J, Serup P, Krull J, Gradwohl G, et al. Opposing actions of Arx and Pax4 in endocrine pancreas development. Genes and Development. 2003;17(20):2591-2603. DOI: http://dx.doi.org/10.1101/gad.269003
7. Gosmain Y, Cheyssac C, Masson MH, Guerardel A, Poisson C, Philippe J. Pax6 is a key component of regulated glucagon secretion. Endocrinology. 2012;153(9):4204-4215. DOI: http://dx.doi.org/10.1210/en.2012-1425
8. Gosmain Y, Marthinet E, Cheyssac C, Guerardel A, Mamin A, Katz LS, et al. Pax6 controls the expression of critical genes involved in pancreatic {alpha} cell differentiation and function. Journal of Biological Chemistry. 2010;285(43):33381-33393. DOI: http://dx.doi.org/10.1074/jbc.M110.147215
9. Hayashi Y, Yamamoto M, Mizoguchi H, Watanabe C, Ito R, Yamamoto S, et al. Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet {alpha}-cells but not of intestinal L-cells. Molecular Endocrinology. 2009;23(12):1990-1999. DOI: http://dx.doi.org/10.1210/me.2009-0296
10. Irwin DM. Molecular evolution of mammalian incretin hormone genes. Regulatory Peptides. 2009;155(1-3):121-130. DOI: http://dx.doi.org/10.1016/j.regpep.2009.04.009
11. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Molecular and Cellular Endocrinology. 2009;297(1-2):127-136. DOI: http://dx.doi.org/10.1016/j.mce.2008.08.012
12. Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, Ford EL, et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metabolism. 2009;9(4):350-361. DOI: http://dx.doi.org/10.1016/j.cmet.2009.02.007
13. Holst JJ, Christensen M, Lund A, de Heer J, Svendsen B, Kielgast U, et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab. 2011;13 Suppl 1:89-94. DOI: http://dx.doi.org/10.1111/j.1463-1326.2011.01452.x
14. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism. 2007;92(4):1249-1255. DOI: http://dx.doi.org/10.1210/jc.2006-1882
15. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocrine Reviews. 1999;20(6):876-913. DOI: http://dx.doi.org/10.1210/er.20.6.876
16. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual ß-cell function. Diabetes. 2011;60(5):1599-1607. DOI: http://dx.doi.org/10.2337/db10-1790
17. Ahren B. Autonomic regulation of islet hormone secretion--implications for health and disease. Diabetologia. 2000;43(4):393-410. DOI: http://dx.doi.org/10.1007/s001250051322
Review
For citations:
Petunina N.A., Trukhina L.V., Sinicyna E.I., Shestakova M.V. Glucagon and alpha-cells as a novel therapeutic target in the management of diabetes mellitus. Diabetes mellitus. 2013;16(3):35-40. (In Russ.) https://doi.org/10.14341/2072-0351-815
Views:
7687
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
